|
TGTX | Tg Therapeutics, Inc. |
|
|
TGTX | Tg Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.12 |
| Leverage | 40.76% |
| Market Cap | $ 4.9B |
| PE | 11.16 |
| Dividend Yield | 0.00% |
| Profit | $ 443.0m |
| Margin | 81.75% |
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.